Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 5/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14174239 | 0.94 | TDP1 (0.34) | NR1I2HTR2CKDM4ETDP1ALDH1A1 | |
| SCHEMBL14949253 | 0.94 | NR1I2 (0.33) | NR1I2HTR2CKDM4ETDP1ALDH1A1 | |
| SCHEMBL12306379 | 0.87 | ALDH1A1 (0.33) | NR1I2HTR2CKDM4ETDP1ALDH1A1 | |
| SCHEMBL3394035 | 0.85 | KDM4E (0.33) | NR1I2KDM4ETDP1ALDH1A1MAPT | |
| SCHEMBL14174240 | 0.85 | KDM4E (0.33) | NR1I2KDM4ETDP1ALDH1A1MAPT | |
| SCHEMBL14184484 | 0.85 | KDM4E (0.33) | NR1I2KDM4ETDP1ALDH1A1MAPT | |
| SCHEMBL13457555 | 0.84 | KDM4E (0.32) | NR1I2KDM4ETDP1ALDH1A1MAPT | |
| SCHEMBL6238496 | 0.82 | TDP1 (0.51) | NR1I2HTR2CKDM4ETDP1ALDH1A1 | |
| SCHEMBL6238490 | 0.82 | TDP1 (0.51) | NR1I2HTR2CKDM4ETDP1ALDH1A1 | |
| SCHEMBL14174247 | 0.80 | KDM4E (0.31) | NR1I2KDM4ETDP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161268-A1 | Carbacephem beta-lactam compounds for the treatment of bacterial infections | Trine Pharmaceuticals, Inc. (US) | 2010-03-10 | — | — | EP | disclosed |
| EP-1618106-B1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | TRINE PHARMACEUTICALS INC (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080146535-A1 | Compositions comprising carbacephem beta-lactam antibiotics and beta-lactamase inhibitors | BLANCA PHARMACEUTICALS, INC. | 2008-06-19 | — | — | US | disclosed |
| US-7109190-B2 | Carbacephem β-lactam antibiotics | TRINE PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050004095-A1 | Carbacephem beta-lactam antibiotics | TRINE PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146535-A1 | Compositions comprising carbacephem beta-lactam antibiotics and beta-lactamase inhibitors | MGAM, CMBL, MGAM2 | NR1I2 3448/4885HTR2C 3983/4885KDM4E 1002/4885 |
| US-20050004095-A1 | Carbacephem beta-lactam antibiotics | MGAM, CUTA, CMBL | NR1I2 3828/4885HTR2C 3261/4885KDM4E 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.